Table 3.
S(1*) Distribution | ACN Assump. |
|
|||
---|---|---|---|---|---|
Est. (95% CI) γ = 1 | Ign. int.2 | 95% EUI1 | |||
Same as RV144 (Fig. 3A) | for X = 0 | 34.6 (11.1, 65.8) | (27.7, 43.3) | (8.9, 82.2) | |
Higher3 for X* = 0 (Fig. 3B) | for X = 0 | 36.1 (11.0, 65.9) | (28.9, 45.2) | (8.8, 82.4) | |
Higher3 for X* = 1 (Fig. 3C) | for X = 0 | 36.6 (11.0, 65.9) | (29.3, 45.7) | (8.8, 82.4) | |
Higher3 for All (Fig. 3D) | for X = 0 | 38.1 (10.6, 67.0) | (30.5, 47.6) | (8.5, 83.7) | |
Same as RV144 (Fig. 4A) | for X = 1 | 38.0 (14.0, 67.2) | (30.4, 47.5) | (10.9, 84.1) | |
Higher3 for X* = 0 (Fig. 4B) | for X = 1 | 42.7 (14.0, 68.5) | (34.2, 53.4) | (11.2, 85.7) | |
Higher3 for X* = 1 (Fig. 4C) | for X = 1 | 39.2 (14.0, 68.5) | (31.3, 49.0) | (11.2, 85.7) | |
Higher3 for All (Fig. 4D) | for X = 1 | 43.9 (16.5, 75.5) | (35.1, 54.9) | (13.2, 94.3) | |
Higher4 for All | for X = 0 | 40.7 (6.7, 74.2) | (31.8, 50.9) | (2.6, 93.4) | |
Higher4 for All | for X = 1 | 55.8 (23.2, 94.0) | (44.8, 70.1) | (19.3, 100) | |
Model Adding a v = 1 Strain Assuming
| |||||
Higher3 for All | for X = 0 | 52.3 (15.1, 92.7) | (41.8, 65.3) | (12.0, 100) | |
Higher3 for All | for X = 1 | 60.3 (23.6, 100) | (48.2, 75.4) | (18.8, 100) | |
Higher4 for All | for X = 0 | 55.8 (6.3, 100) | (44.1, 69.6) | (0.0, 100) | |
Higher4 for All | for X = 1 | 76.7 (33.3, 100) | (61.5, 96.3) | (26.9, 100) |
The estimation is done as described in Table 2, except for new elements listed in this table.
Computed for ϕ(t, v|s1, x) = γ with γ ranging over [ Γ] for Γ = 1.25, where ϕ(t, v|s1, x) ≡ VE*(t = 39, v|s1, x)/VE(t = 39, v|s1, x).
Estimation scenario of equal support of (X*, S(1*)) and (X, S(1)), where the distribution of S(1*) follows a modification of F̂*(s1|x) from RV144 data (Figure 2) by moving a random sample of 75% of the original Si(1) values with percentile p ≤ 0.50 in RV144 to the percentile p* = p + 0.50.
Estimation scenario of equal support of (X*, S(1*)) and (X, S(1)), where the distribution of S(1*) is uniformly distributed in the highest range of immune responses supported by the binding assay, [9, 10.1].